Clinical trials: Corneal Dystrophy
Corneal Endothelial Dystrophy, Corneal Edema
Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
The purpose of this study is to assess off-label use of loteprednol etabonate 0.25% ophthalmic suspension (Eysuvis) for prevention of immunologic rejection in the first year after Descemet membrane endothelial keratoplasty…
- Trial name
- NCT05136443
- Testing
- loteprednol etabonate 0.25% ophthalmic suspension
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Price Vision Group
Bullous Keratopathy, Corneal Erosion
Air Optix® Night and Day® Aqua Therapeutic Wear
The purpose of this study is to support the safety and performance assessment of Air Optix Night and Day Aqua (AONDA) soft contact lenses for therapeutic use in accordance with updated EU Medical Device Regulation (MDR)…
- Conditions
- Bullous Keratopathy, Corneal Erosion, Entropion, Corneal Edema
- Trial name
- NCT05956535
- Testing
- Lotrafilcon A contact lenses, Balafilcon A contact lenses
- Where
- 3 sites in United States
- Volunteers
- 168 people
- Sponsor
- Alcon Research
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
- Trial name
- EPPIK (NCT05003986)
- Testing
- Sparsentan
- Where
- 47 sites in United States, Germany and 6 more
- Volunteers
- 67 people
- Sponsor
- Travere Therapeutics, Inc.
Corneal Dystrophy
Study of the Prevalence of TGFBI Corneal Dystrophies
To determine the prevalence of 5 specific corneal dystrophies in a subgroup of patients seeking refractive surgery, and to use that information to inform them and their refractive surgeons of the presence of the corneal…
- Trial name
- NCT02746055
- Volunteers
- 20,000 people
- Sponsor
- Avellino Labs USA, Inc.
Fuchs' Dystrophy, Bullous Keratopathy
Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)
The purpose of this study is to compare two different commonly used steroid dosing regimens after Descemet's membrane endothelial keratoplasty (DMEK) transplant surgery.
- Trial name
- NCT01448213
- Testing
- Prednisolone acetate, Fluorometholone
- Where
- 2 sites in United States, Germany
- Volunteers
- 264 people
- Sponsor
- Price Vision Group
Corneal Dystrophy, Epithelial Basement Membrane
Optimizing the Ocular Surface Prior to Cataract Surgery
Prospective study to evaluate the efficacy of using self-retained cryopreserved amniotic membrane after debridement in treating Epithelial Base Membrane Dystrophy (EBMD) to optimize the ocular surface integrity and intraocular…
- Trial name
- NCT02766907
- Testing
- cryopreserved amniotic membrane
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- BioTissue Holdings, Inc
Fuchs' Endothelial Corneal Dystrophy
Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis
The objective of this study is to investigate the effect of K-321 in patients with Fuchs endothelial corneal dystrophy (FECD) after descemetorhexis.
- Trial name
- NCT04250207
- Testing
- K-321 Solution
- Where
- 29 sites in United States, Australia and 3 more
- Volunteers
- 65 people
- Sponsor
- Kowa Research Institute, Inc.
Fuchs Endothelial Corneal Dystrophy
A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)
This is a Phase IIa study to assess efficacy and safety of STN1010904 ophthalmic suspension (0.03%, and 0.1 %), twice daily dosing when compared to Placebo in subjects diagnosed with Fuchs Endothelial Corneal Dystrophy (FECD).
- Trial name
- PHANTOM (NCT05376176)
- Testing
- STN1010904 ophthalmic suspension 0.03% BID, STN1010904 ophthalmic suspension 0.1% BID
- Where
- 15 sites in United States, France and 1 more
- Volunteers
- 86 people
- Sponsor
- Santen Inc.
Fuchs Endothelial Corneal Dystrophy, Fuchs
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.
- Trial name
- NCT07024693
- Testing
- DT-168
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Design Therapeutics, Inc.
Bullous Keratopathy, Corneal Erosion
AONDA Therapeutic Indication Study I
This study will be used to support assessment of AIR OPTIX® NIGHT \& DAY® AQUA (AONDA) Soft Contact Lenses' safety and performance in accordance with updated European Union Medical Device Regulation (EU MDR) requirements.
- Conditions
- Bullous Keratopathy, Corneal Erosion, Entropion, Corneal Edema
- Trial name
- NCT05891106
- Testing
- Lotrafilcon A contact lenses
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Alcon Research
Fuchs' Endothelial Dystrophy, Corneal Edema
ODM 5 in the Treatment of Corneal Edematous Fuchs' Endothelial Dystrophy
Clinical observation to confirm the clinical safety and efficacy of ODM 5 in the treatment of corneal edema caused by Fuchs' endothelial dystrophy.
- Trial name
- NCT02332109
- Testing
- ODM 5
- Where
- 4 sites in Germany
- Volunteers
- 29 people
- Sponsor
- TRB Chemedica AG
Corneal Edema, Corneal Endothelial Dysfunction
Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema
Corneal edema is the most common indication for corneal transplantation, accounting for approximately 70% of penetrating keratoplasty (PK), and 100% of endothelial keratoplasty (EK) procedures annually.
- Conditions
- Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Fuchs Dystrophy
- Trial name
- NCT04894110
- Testing
- EO2002, EO2002 low dose, EO2002 mid dose
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- Emmecell
Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy
A Phase 1/ Phase 2 Study of TTHX1114(NM141)
Prospective, multicenter, randomized, masked, vehicle-controlled, dose-escalation study
- Conditions
- Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction
- Trial name
- INTREPID (NCT04520321)
- Testing
- TTHX1114(NM141)
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- Trefoil Therapeutics, Inc.
Fuchs Endothelial Dystrophy
Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
The study objective is to determine whether use of Rhopressa improves the ability of corneal endothelial cells to maintain appropriate corneal hydration in patients with Fuchs endothelial corneal dystrophy (FECD), which could…
- Trial name
- NCT04051463
- Testing
- Netarsudil Ophthalmic Solution
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Price Vision Group
Corneal Endothelial Dystrophy
A Safety and Efficacy Trial of TTHX1114 in People With CED
Expanded access, open label study at a single dose level in patients with CED that in the opinion of the investigators might benefit from TTHX1114
- Trial name
- OPTIC (NCT04812067)
- Testing
- TTHX1114
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Trefoil Therapeutics, Inc.
Fuchs Endothelial Corneal Dystrophy
A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
A study to assess the safety and efficacy of K-321 in participants with FECD after simultaneous cataract surgery and descemetorhexis.
- Trial name
- NCT05826353
- Testing
- Ripasudil
- Where
- 43 sites in United States, Canada and 4 more
- Volunteers
- 110 people
- Sponsor
- Kowa Research Institute, Inc.
FSGS, MCD
A Study to Evaluate the Safety, Tolerability and PK of SK-09
This Phase 1 trial consists of three parts: Part 1 is a Single Ascending Dose (SAD) study, Part 2 is a Multiple Ascending Dose (MAD) study. Both parts adopt a randomized, double-blind, placebo-controlled design.
- Trial name
- NCT07267026
- Testing
- SK-09
- Where
- Australia
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Consun Pharmaceutical Group
pMN, IgAN
Atacicept in Multiple Glomerular Diseases
A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.
- Conditions
- pMN, IgAN, Nephrotic Syndrome, MCD
- Trial name
- NCT06983028
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Vera Therapeutics, Inc.
Corneal Edema
A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy
Two different dosing regimens (QD and BID) of netarsudil will be studied to evaluate their efficacy in reducing or resolving corneal edema in subjects with FCD.
- Trial name
- Fuchs (NCT04498169)
- Testing
- Netarsudil Ophthalmic
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Aerie Pharmaceuticals
Fuchs Endothelial Corneal Dystrophy
A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
A study to assess the safety and efficacy of K-321 in participants with FECD after descemetorhexis.
- Trial name
- NCT05795699
- Testing
- Ripasudil
- Where
- 50 sites in United States, Canada and 4 more
- Volunteers
- 107 people
- Sponsor
- Kowa Research Institute, Inc.